Key Differences: Wegovy vs Mounjaro Mechanisms Explained
Wegovy vs Mounjaro: Why Choose Private Prescription in the UK
The difference between Wegovy and Mounjaro becomes particularly relevant when accessing treatment privately rather than through NHS pathways. NHS weight management services typically require GP referral to specialist services, with waiting lists often exceeding six months and strict eligibility criteria. Private prescription eliminates these barriers, allowing eligible patients to access either Wegovy or Mounjaro through clinical assessment without GP involvement. Our GPhC-registered pharmacy (#9012878) provides the same genuine medications prescribed on the NHS, with transparent pricing and next-day delivery.
Understanding the difference between Wegovy and Mounjaro helps patients and prescribers choose the most appropriate treatment. Wegovy utilises semaglutide, a GLP-1 receptor agonist proven in the STEP clinical trial programme, whilst Mounjaro contains tirzepatide, which targets both GIP and GLP-1 receptors. Both require prescription-only medicine status and must be used alongside a reduced-calorie diet and increased physical activity. Private prescription offers faster access to either option, with our streamlined assessment process typically completed within 24-72 hours.
Pricing Comparison: Wegovy and Mounjaro Private Prescription Costs
When comparing the difference between Wegovy and Mounjaro pricing, Wegovy starts from £79.99 for the 0.25mg starter dose, progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg) to £209.99 for the 2.4mg maintenance dose. Our bundle options provide convenient multi-month supplies, such as the Intro Duo (0.25mg & 0.5mg) for £169.99 or the Ultimate Stability Trio (three 2.4mg pens) for £649.99. New customers can apply discount code FIRST40 at checkout, whilst returning customers use DOSE25, with these prices already reflecting the discounted rates.
The difference between Wegovy and Mounjaro extends beyond active ingredients to practical considerations like cost per treatment cycle. Wegovy's established dosing schedule provides predictable monthly costs, particularly beneficial for budgeting private treatment. Our bundle pricing offers the convenience of fewer orders and Reliable Supply continuity, eliminating concerns about stock availability. All prices include prescriber review, with standard assessment completed within three working days or express 24-hour review available for urgent requirements.
Clinical Evidence: Wegovy vs Mounjaro Research Findings
The clinical difference between Wegovy and Mounjaro stems from their distinct trial programmes and mechanisms of action. Wegovy's evidence base includes the comprehensive STEP trials, with STEP 1 demonstrating approximately 15% average weight loss at 68 weeks compared to 2.4% with placebo, as published by Wilding et al. in the New England Journal of Medicine, 2021. The recent SELECT cardiovascular outcomes trial showed a 20% reduction in major adverse cardiovascular events amongst patients taking semaglutide.
Mounjaro's SURMOUNT trials evaluated tirzepatide's dual receptor approach, though direct head-to-head comparison between the treatments remains limited due to different trial designs and patient populations. Both medications require clinical assessment to determine suitability, with prescribers considering individual patient factors when evaluating the difference between Wegovy and Mounjaro for specific cases.
How Wegovy Works: GLP-1 Receptor Mechanism
Understanding how Wegovy works highlights a key difference between Wegovy and Mounjaro at the molecular level. Wegovy contains semaglutide, which mimics the action of GLP-1 (glucagon-like peptide-1), a natural hormone released by the intestines after eating. This mechanism reduces appetite by acting on brain centres that control hunger and satiety, promoting feelings of fullness after smaller meals. Semaglutide also slows gastric emptying, prolonging the sensation of satisfaction after eating. The once-weekly injection delivered via Novo Nordisk's FlexTouch pen provides consistent therapeutic levels throughout the week. Clinical studies suggest this mechanism may also reduce food cravings, particularly for high-calorie foods, supporting long-term weight management goals.
Private Prescription Process: Assessment to Delivery
Our streamlined private prescription process eliminates the complexity often associated with accessing weight management treatments. The initial clinical assessment takes approximately three minutes, covering medical history, current medications, and weight management goals to help determine the difference between Wegovy and Mounjaro suitability. Our qualified prescribers review each application within three working days (or 24 hours with express service), ensuring thorough clinical evaluation whilst maintaining rapid access. Once approved, medications are dispatched via next-day delivery using temperature-controlled cold-chain logistics to preserve medication integrity. Our GPhC-registered pharmacy (#9012878) handles all dispensing, ensuring full regulatory compliance and patient safety. The entire process from assessment to delivery typically completes within 4-5 days, compared to months via traditional NHS pathways.
Storage and Practical Considerations: Wegovy Advantages
A practical difference between Wegovy and Mounjaro involves storage requirements that affect daily use and travel convenience. Wegovy maintains stability for up to six weeks at room temperature (below 30°C) once removed from refrigeration, compared to Mounjaro's 21-day limit. This advantage proves particularly valuable for business travel, holidays, or situations where refrigerated storage becomes challenging. Both medications require initial refrigerated storage at 2-8°C until first use, and our cold-chain delivery ensures products arrive in optimal condition. The FlexTouch pen system used for Wegovy provides precise dose delivery with minimal injection volume, whilst the weekly dosing schedule offers convenience compared to daily medications. Proper dose escalation remains mandatory for both treatments, with our prescribers providing detailed guidance on progression schedules.
Mechanism Comparison: Single vs Dual Receptor Targeting
The fundamental difference between Wegovy and Mounjaro lies in their receptor targeting approaches. Wegovy's semaglutide specifically targets GLP-1 receptors, providing proven efficacy through this single pathway with extensive real-world experience since its approval. This focused mechanism offers predictable effects and well-characterised side effect profiles, making it suitable for patients seeking established treatment protocols. The wealth of clinical data supporting semaglutide spans multiple indications and patient populations, providing confidence in long-term outcomes.
Mounjaro's tirzepatide represents a newer dual agonist approach, targeting both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors simultaneously. This mechanism theoretically provides enhanced efficacy through multiple pathways, though real-world experience remains more limited compared to semaglutide. When considering the difference between Wegovy and Mounjaro, prescribers evaluate individual patient factors including treatment history, comorbidities, and personal preferences to determine the most appropriate option.
Making Your Choice: Wegovy and Mounjaro Through EverydayMeds
Both Wegovy and Mounjaro are available through our private prescription service, with our clinical team helping determine which option best suits your individual circumstances. The difference between Wegovy and Mounjaro extends beyond mechanism to practical factors like storage convenience, dosing schedules, and cost considerations. Our transparent pricing structure eliminates hidden fees, whilst our discount codes FIRST40 (new customers) and DOSE25 (returning customers) are applied at checkout to reach our published prices. We maintain consistent stock levels of all Wegovy doses, ensuring treatment continuity without the supply interruptions that sometimes affect NHS services. Our prescribers provide ongoing support throughout your treatment journey, with regular review appointments available to monitor progress and adjust treatment as needed. Starting your weight management journey through private prescription offers immediate access to these proven treatments whilst maintaining the flexibility to transfer to NHS care if circumstances change.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
